Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors

被引:21
|
作者
Villa, Juan Antonio [1 ,2 ]
Pike, Daniel P. [1 ,2 ]
Patel, Kunjan B. [1 ,2 ]
Lomonosova, Elena [1 ,2 ]
Lu, Gaofeng [1 ,2 ,3 ]
Abdulqader, Roz [1 ,2 ]
Tavis, John E. [1 ,2 ]
机构
[1] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA
[2] St Louis Univ, Sch Med, St Louis Univ Liver Ctr, St Louis, MO 63104 USA
[3] Zhengzhou Univ, Affiliated Hosp 2, Dept Gastroenterol, Zhengzhou, Henan, Peoples R China
关键词
Hepatitis B virus; DNA virus; RNA processing; Ribonuclease; Endoribonuclease; STRAND DNA-SYNTHESIS; RNASE-H; REVERSE-TRANSCRIPTASE; RNA/DNA HYBRID; VIRAL-DNA; HIV-1; RT; POLYMERASE; REPLICATION; DOMAIN; EXPRESSION;
D O I
10.1016/j.antiviral.2016.06.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatitis B virus (HBV) reverse transcription requires coordinated function of the reverse transcriptase and ribonuclease H (RNaseH) activities of the viral polymerase protein. The reverse transcriptase has been biochemically characterized, but technical difficulties have prevented both assessment of the RNaseH and development of high throughput inhibitor screens against the RNaseH. Expressing the HBV RNaseH domain with both maltose binding protein and hexahistidine tags led to stable, high-level accumulation of the RNaseH in bacteria. Nickel-affinity purification in the presence of Mg2+ and ATP removed co-purifying bacterial chaperones and yielded nearly pure monomeric recombinant enzyme. The endonucleolytic RNaseH activity required an DNA:RNA duplex >= 14 nt, could not tolerate a stem-loop in either the RNA or DNA strands, and could tolerate a nick in the DNA strand but not a gap. The RNaseH had no obvious sequence specificity or positional dependence within the RNA, and it cut the RNA at multiple positions even within the minimal 14 nt duplex. The RNaseH also possesses a processive 3'-5' exoribonuclease activity that is slower than the endonucleolytic reaction. These results are consistent with the HBV reverse transcription mechanism that features an initial endoribonucleolytic cut, 3'-5' degradation of RNA, and a sequence-independent terminal RNA cleavage. These data provide support for ongoing anti-RNaseH drug discovery efforts. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:186 / 195
页数:10
相关论文
共 50 条
  • [1] Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus
    Tramontano, Enzo
    Corona, Angela
    Menendez-Arias, Luis
    ANTIVIRAL RESEARCH, 2019, 171
  • [2] The hepatitis B virus ribonuclease H as a drug target
    Tavis, John E.
    Lomonosova, Elena
    ANTIVIRAL RESEARCH, 2015, 118 : 132 - 138
  • [3] The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes
    Tavis, John E.
    Cheng, Xiaohong
    Hu, Yuan
    Totten, Michael
    Cao, Feng
    Michailidis, Eleftherios
    Aurora, Rajeev
    Meyers, Marvin J.
    Jacobsen, E. Jon
    Parniak, Michael A.
    Sarafianos, Stefan G.
    PLOS PATHOGENS, 2013, 9 (01)
  • [4] Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors
    Bradley, Daniel P.
    Valkner, Caleb J.
    Li, Qilan
    Gasonoo, Makafui
    Meyers, Marvin J.
    Prifti, Georgia-Myrto
    Moianos, Dimitrios
    Zoidis, Grigoris
    Zlotnick, Adam
    Tavis, John E.
    PLOS PATHOGENS, 2025, 21 (02)
  • [5] Fermentation, purification and characterization of a new antiviral ribonuclease produced by Bacillus cereus
    Zhou, Wen-Wen
    He, Yun-Long
    Niu, Tian-Gui
    Zhong, Jian-Jiang
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 2009, 108 : S115 - S115
  • [6] Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H
    Lomonosova, Elena
    Daw, Jil
    Garimallaprabhakaran, Aswin K.
    Agyemang, Nana B.
    Ashani, Yashkumar
    Murelli, Ryan P.
    Tavis, John E.
    ANTIVIRAL RESEARCH, 2017, 144 : 164 - 172
  • [7] Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H
    Tavis, John E.
    Zoidis, Grigoris
    Meyers, Marvin J.
    Murelli, Ryan P.
    ACS INFECTIOUS DISEASES, 2019, 5 (05): : 655 - 658
  • [8] Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice
    Long, Kelly R.
    Lomonosova, Elena
    Li, Qilan
    Ponzar, Nathan L.
    Villa, Juan A.
    Touchette, Erin
    Rapp, Stephen
    Liley, R. Matt
    Murelli, Ryan P.
    Grigoryan, Alexandre
    Buller, R. Mark
    Wilson, Lisa
    Bial, John
    Sagartz, John E.
    Tavis, John E.
    ANTIVIRAL RESEARCH, 2018, 149 : 41 - 47
  • [9] The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target
    Niklasch, Matthias
    Zimmermann, Peter
    Nassal, Michael
    BIOMEDICINES, 2021, 9 (11)
  • [10] Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors
    Lu, Gaofeng
    Villa, Juan Antonio
    Donlin, Maureen J.
    Edwards, Tiffany C.
    Cheng, Xiaohong
    Heier, Richard F.
    Meyers, Marvin J.
    Tavis, John E.
    ANTIVIRAL RESEARCH, 2016, 135 : 24 - 30